Table 4.
Clinical Trials: Immunotherapy of Advanced TNBC
| Trial | Phase | Treatment | Type of Drug | ORR | mPFS (Months) | mOS (Months) | Incidence of TRAEs | |
|---|---|---|---|---|---|---|---|---|
| Total | Grade≥3 | |||||||
| KEYNOTE-012 | 1b | Pembro | Anti-PD-1 | 18.5% | NR | NR | 56.3% | 15.6% |
| KEYNOTE-028 | 1b | Pembro | Anti-PD-1 | 12.0% | 1.8 | 8.6 | 64.0% | 16.0% |
| KEYNOTE-086 cohort A | 2 | Pembro | Anti-PD-1 | 5.3% | 2.0 | 9.0 | 60.6% | 12.9% |
| KEYNOTE-086 cohort B | 2 | Pembro | Anti-PD-1 | 21.4% | 2.1 | 18.0 | 63.1% | <1% |
| JAVELIN solid tumor | 1b | Avelumab | Anti-PD-1 | 5.2% | NR | NR | 68.5% | 13.7% |
| NCT01375842 | 1 | Atezo | Anti-PD-L1 | 24.0% (first-line) |
1.4 | 17.6 | 63.0% | 11.0% |
| IMpassion130 | 3 | Atezo + nab-P vs Placebo + nab-P |
Anti-PD-L1 + Chemo | NR | 7.2 vs 5.5 | 21.3 vs 17.6 | 99.3% vs 97.9% | 48.7% vs.42.2% |
| IMpassion130 updated | 21.0 vs 18.7 | 97.0%vs 94.0% | 54.0% vs 38.0% | |||||
| NCT01633970 | 1b | Atezo + nab-P | Anti-PD-L1 + Chemo | 39.4% | 5.5 | 14.7 | 100% | 73.0% |
| KEYNOTE-162 | 2 | Pembro + Niraparib | Anti-PD-1 + PARPi |
67.0% (BRCAmut) |
8.1 | NR | 98.2% | 50.0% |
| NCT03394287 | 2 | Camre + Apatinib d1-14 vs Camre + Apatinib d1-7 | Anti-PD-1 + Antiangi |
43.3%vs 0 | 3.7 vs 1.9 | NR | 100% VS 90% | 26.7% vs 20.0% |
Abbreviations: mPFS, median progression-free survival; mOS, overall survival; Pembro, pembrolizumab; Atezo, atezolizumab; nab-P, nab-paclitaxel; Chemo, chemotherapy; Camre, camrelizumab; PARPi, PARP inhibitor; Antiangi, antiangiogenesis.